Identification of CMTM6 and CMTM4 as PD-L1 protein regulators

Nature

Volumn 549, Issue 7670, 2017, Pages 106-110

  Mezzadra, Riccardo ^a   Sun, Chong ^a   Jae, Lucas T ^a,f   Gomez Eerland, Raquel ^a   De Vries, Evert ^a   Wu, Wei ^b,c   Logtenberg, Meike E W ^a   Slagter, Maarten ^a   Rozeman, Elisa A ^a   Hofland, Ingrid ^a   Broeks, Annegien ^a   Horlings, Hugo M ^a   Wessels, Lodewyk F A ^a   Blank, Christian U ^a   Xiao, Yanling ^a   Heck, Albert J R ^b,c   Borst, Jannie ^a   Brummelkamp, Thijn R ^a,d,e   Schumacher, Ton N M ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c NETHERLANDS PROTEOMICS CENTRE   (Netherlands)

^d ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^e Cancer GenomiCsnl   (Netherlands)

^f UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CMTM4 PROTEIN; CMTM6 PROTEIN; REGULATOR PROTEIN; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; CMTM4 PROTEIN, HUMAN; MARVEL DOMAIN CONTAINING PROTEIN; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN BINDING;

CANCER; CELLS AND CELL COMPONENTS; GENE EXPRESSION; GENETIC ANALYSIS; IDENTIFICATION METHOD; INHIBITOR; PROTEIN; TUMOR;

A-375 CELL LINE; ARTICLE; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DENDRITIC CELL; GENETIC COMPLEMENTATION; GENETIC SCREENING; HAPLOIDY; HUMAN; HUMAN CELL; LUNG NON-SMALL CELL CARCINOMA CELL LINE; MODIFIER GENE; PRIMARY CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; BIOSYNTHESIS; CHEMISTRY; CRISPR CAS SYSTEM; GENETICS; MELANOMA; METABOLISM; PROTEIN STABILITY; TUMOR CELL LINE; UBIQUITINATION;

B7-H1 ANTIGEN; CELL LINE, TUMOR; CRISPR-CAS SYSTEMS; DENDRITIC CELLS; GENETIC COMPLEMENTATION TEST; HAPLOIDY; HUMANS; MARVEL DOMAIN-CONTAINING PROTEINS; MELANOMA; PROTEIN BINDING; PROTEIN STABILITY; UBIQUITINATION;

EID: 85029041186     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature23669     Document Type: Article

References (31)

1. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
2. Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465 (2012).
3. Ansell, S. M. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 372, 311-319 (2015).
4. Powles, T. et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515, 558-562 (2014).
5. Garon, E. B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018-2028 (2015).
6. Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509-2520 (2015).
7. Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803-1813 (2015).
8. Nghiem, P. T. et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N. Engl. J. Med. 374, 2542-2552 (2016).
9. Ferris, R. L. et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 375, 1856-1867 (2016).
10. Lee, S. J. et al. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-γ-induced upregulation of B7-H1 (CD274). FEBS Lett. 580, 755-762 (2006).
11. Kataoka, K. et al. Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers. Nature 534, 402-406 (2016).
12. Casey, S. C. et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science 352, 227-231 (2016).
13. Dorand, R. D. et al. Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity. Science 353, 399-403 (2016).
14. Li, C.-W. et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat. Commun. 7, 12632 (2016).
15. Lim, S. O. et al. Deubiquitination and stabilization of PD-L1 by CSN5. Cancer Cell 30, 925-939 (2016).
16. Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563-567 (2014).
17. Ribas, A. & Hu-Lieskovan, S. What does PD-L1 positive or negative mean? J. Exp. Med. 213, 2835-2840 (2016).
18. Carette, J. E. et al. Haploid genetic screens in human cells identify host factors used by pathogens. Science 326, 1231-1235 (2009).
19. Carette, J. E. et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 477, 340-343 (2011).
20. Brockmann, M. et al. Genetic wiring maps of single-cell protein states reveal an off-switch for GPCR signalling. Nature 546, 307-311 (2017).
21. Platanias, L. C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 5, 375-386 (2005).
22. Han, W. et al. Identification of eight genes encoding chemokine-like factor superfamily members 1-8 (CKLFSF1-8) by in silico cloning and experimental validation. Genomics 81, 609-617 (2003).
23. Xiao, Y. et al. Identification of the common origins of osteoclasts, macrophages, and dendritic cells in human hematopoiesis. Stem Cell Rep. 4, 984-994 (2015).
24. Chen, Z. et al. The ubiquitin ligase Stub1 negatively modulates regulatory T cell suppressive activity by promoting degradation of the transcription factor Foxp3. Immunity 39, 272-285 (2013).
25. Wei, F. et al. Strength of PD-1 signaling differentially afects T-cell effector functions. Proc. Natl Acad. Sci. USA 110, E2480-E2489 (2013).
26. Miyazaki, A., Yogosawa, S., Murakami, A. & Kitamura, D. Identification of CMTM7 as a transmembrane linker of BLNK and the B-cell receptor. PLoS ONE 7, e31829 (2012).
27. Benjamini, Y. & Hochberg, Y. Controlling the False discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B 57, 289-300 (1995).
28. Kemper, K. et al. Intra- and inter-tumor heterogeneity in a vemurafenibresistant melanoma patient and derived xenografts. EMBO Mol. Med. 7, 1104-1118 (2015).
29. Lackner, D. H. et al. A generic strategy for CRISPR-Cas9-mediated gene tagging. Nat. Commun. 6, 10237 (2015).
30. Doench, J. G. et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat. Biotechnol. 34, 184-191 (2016).
31. Jorritsma, A. et al. Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. Blood 110, 3564-3572 (2007).